Nucleoside analogues for the treatment of coronavirus infections
Open accessAbstract
Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3' to 5' proofreading exoribonuclease unique to CoVs. Recently, a promising nucleoside analogue with broad-spectrum activity against CoVs has been identified. This review will discuss progress made in the development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Host vesicular trafficking, translation, RNA splicing, nucleotide synthesis and glycolysis pathway proteins were upregulated following infection, and targeting these processes with inhibitors revealed potential therapeutic targets.
“Consistently, host vesicular trafficking, translation, RNA splicing, nucleotide synthesis and glycolysis pathway proteins were upregulated following infection143,144 and targeting these processes with inhibitors revealed potential therapeutic targets158,159.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C.-K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,956 · see citing works
Coronaviruses — drug discovery and therapeutic options
Zumla, A. I., Chan, J. F., Azhar, E. I., Hui, D. S. C., & Yuen, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,689 · see citing works
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · see citing works
Self-citationAgostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418 · see citing works
Self-citationClinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,405 · see citing works
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 996 · see citing works
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 653 · see citing works
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Tongeren, S. A. V., Dŏng, L., Retterer, C. J., Eaton, B., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 616 · see citing works
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lü, H., Fan, K. W., Cheng, V. C., Tsui, W., Hung, I. F., & Lee, T. S. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.03.003 · Cited by 535 · see citing works
Middle East Respiratory Syndrome
Arabi, Y. M., Balkhy, H. H., Hayden, F. G., Bouchama, A., Luke, T., Baillie, J. K., Al-Omari, A., Hajeer, A. H., Senga, M., Denison, M. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1408795 · Cited by 518 · see citing works
Self-citationGS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Lo, M. K., Jordan, R., Arvey, A. J., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D. S., Clarke, M. O., et al. (2017) · Scientific Reports · doi:10.1038/srep43395 · Cited by 514 · see citing works
Omrani, A. S., Saad, M. M., Baig, K. M., Bahloul, A., Abdul-Matin, M., Aidaroos, A. Y. A., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493 · see citing works
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445 · see citing works
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 428 · see citing works
Self-citationStructural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Ferrón, F., Subissi, L., de Morais, A. T. S., Le, T.-T.-N., Sevajol, M., Gluais, L., Decroly, É., Vonrhein, C., Bricogne, G., Canard, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718806115 · Cited by 407 · see citing works
Mehand, M. S., Al‐Shorbaji, F., Millett, P. D., & Murgue, B. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.09.009 · Cited by 394 · see citing works
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F., Chan, K., Kao, R. Y. T., To, K. K., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385 · see citing works
High Fidelity of Murine Hepatitis Virus Replication Is Decreased in nsp14 Exoribonuclease Mutants
Eckerle, L. D., Lu, X., Sperry, S. M., Choi, L., & Denison, M. R. (2007) · Journal of Virology · doi:10.1128/jvi.01296-07 · Cited by 328 · see citing works
Self-citationAl‐Tawfiq, J. A., Momattin, H., Dib, J. G., & Memish, Z. A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.12.003 · Cited by 322 · see citing works
Molecular pathology of emerging coronavirus infections
Gralinski, L. E., & Baric, R. S. (2014) · The Journal of Pathology · doi:10.1002/path.4454 · Cited by 315 · see citing works
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J. A., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 274 · see citing works
And the MIRACLE trial group, Arabi, Y. M., Alothman, A. F., Balkhy, H. H., Al‐Dawood, A., AlJohani, S. M., Harbi, S. A. A., Kojan, S. M., Jeraisy, M. A., Deeb, A., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 252 · see citing works
Yoon, J.-J., Toots, M., Lee, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00766-18 · Cited by 239 · see citing works
Stuyver, L. J., Whitaker, T., McBrayer, T. R., Hernández-Santiago, B. I., Lostia, S., Tharnish, P. M., Ramesh, M., Chu, C. K., Jordan, R., Shi, J., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.244-254.2003 · Cited by 200 · see citing works
Urakova, N., Kuznetsova, V., Crossman, D. K., Sokratian, A., Guthrie, D. B., Kolykhalov, A. A., Lockwood, M. A., Natchus, M. G., Crowley, M. R., Painter, G. R., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01965-17 · Cited by 194 · see citing works
Shalhoub, S., Farahat, F. M., Al-Jiffri, A. M. Y., Simhairi, R., Shamma, O., Siddiqi, N., & Mushtaq, A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv085 · Cited by 190 · see citing works
Chu, H., Chan, C.-M., Zhang, X., Wang, Y., Yuan, S., Zhou, J., Au-Yeung, R. K. H., Sze, K. H., Yang, D., Shuai, H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001897 · Cited by 186 · see citing works
Taylor, R., Kotian, P. L., Warren, T. K., et al. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.002 · Cited by 178 · see citing works
Barnard, D. L., Hubbard, V. D., Burton, J., Smee, D. F., Morrey, J. D., Otto, M. J., & Sidwell, R. W. (2004) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020401500102 · Cited by 151 · see citing works
Luo, C.-M., Wang, N., Yang, X., Liu, H.-Z., Zhang, W., Li, B., Hu, B., Peng, C., Geng, Q.-B., Zhu, G.-J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00116-18 · Cited by 150 · see citing works
Cameron, C. E., & Castro, C. D. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200112000-00015 · Cited by 148 · see citing works
Nucleosides for the treatment of respiratory RNA virus infections
Jordan, P. C., Stevens, S., & Deval, J. (2018) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206618764483 · Cited by 142 · see citing works
Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle
Pyrć, K., Bosch, B., Berkhout, B., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01598-05 · Cited by 131 · see citing works
Mechanism of action of ribavirin in the treatment of chronic hepatitis C.
Te, H. S., Randall, G. C., & Jensen, D. M. (2007) · PubMed · Cited by 119 · see citing works
CEPI—a new global R&D organisation for epidemic preparedness and response
Brende, B., Farrar, J., Gashumba, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30131-9 · Cited by 112 · see citing works
Barnard, D. L., Day, C. W., Bailey, K. W., Heiner, M., Montgomery, R. A., Lauridsen, L., Winslow, S. G., Hoopes, J. D., Li, J. K.-K., Lee, J., et al. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.03.001 · Cited by 107 · see citing works
Characterization of β- d - N 4 -Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus
Ehteshami, M., Tao, S., Zandi, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02395-16 · Cited by 101 · see citing works
Quasispecies: From Theory to Experimental Systems
Domingo, E., & Schuster, P. M. (2016) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-23898-2 · Cited by 99 · see citing works
Peters, H. L., Jochmans, D., de Wilde, A. H., Posthuma, C. C., Snijder, E. J., Neyts, J. H., & Seley‐Radtke, K. L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.039 · Cited by 91 · see citing works
SAIJO, M., MORIKAWA, S., FUKUSHI, S., MIZUTANI, T., HASEGAWA, H., NAGATA, N., IWATA, N., & KURANE, I. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.01.003 · Cited by 82 · see citing works
Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections
Gross, A. E., & Bryson, M. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597449 · Cited by 60 · see citing works
Modjarrad, K., Moorthy, V., Embarek, P. B., Kerkhove, M. D. V., Kim, J. H., & Kiény, M.-P. (2016) · Nature Medicine · doi:10.1038/nm.4131 · Cited by 60 · see citing works
Development of Small-Molecule MERS-CoV Inhibitors
Liang, R., Wang, L., Zhang, N., Deng, X., Su, M., Su, Y., Hu, L., He, C., Ying, T., Jiang, S., et al. (2018) · Viruses · doi:10.3390/v10120721 · Cited by 53 · see citing works
Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold
Perales, C., & Domingo, E. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_459 · Cited by 49 · see citing works
Eyer, L., Kondo, H., Zouharová, D., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01028-17 · Cited by 47 · see citing works
Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase
Deval, J., Fung, A. D., Stevens, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154097 · Cited by 35 · see citing works
Huang, K.-W., Hsu, K., Chu, L.-Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00794 · Cited by 29 · see citing works
Theories of Lethal Mutagenesis: From Error Catastrophe to Lethal Defection
Tejero, H., Montero, F., & Nuño, J. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_463 · Cited by 27 · see citing works
Diphoko, T., Gaseitsiwe, S., Kasvosve, I., et al. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0135 · Cited by 16 · see citing works
Flaviviridae viruses use a common molecular mechanism to escape nucleoside analogue inhibitors
Valdés, J. J., Butterill, P. T., & Růžek, D. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.068 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J., & Münch, C. (2020) · Nature · doi:10.1038/s41586-020-2332-7 · Cited by 1,010 · see citing works
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210 · see citing works
Singh, A. K., Kushwaha, P. P., Prajapati, K. S., Shuaib, M., Gupta, S., & Kumar, S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104185 · Cited by 58 · see citing works
- Authors
- Pruijssers, A. J., & Denison, M. R.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Denison, Mark R
- Venue
- Current Opinion in Virology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 35
- Pages
- 57-62
- ISSN
- 1879-6257 (ISSN-L)
- PMC
- PMC7102703
- OpenAlex
- W2945440984
- Cited by
- 196
- References
- 51
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 41 · 2021: 56 · 2020: 57 · 2019: 1
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Opinion in Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (U19 AI109680, R01 AI132178, R01 AI108197)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- nucleoside analogues, nucleotide analogues, coronavirus infection, SARS-CoV, MERS-CoV, antiviral drug discovery, 3'-5' exoribonuclease, viral RNA synthesis, combination therapy, zoonotic coronaviruses
- MeSH terms
- Animals, Antiviral Agents, Drug Therapy, Combination, Exoribonucleases, Humans, Nucleosides, Virus Replication, Coronavirus, Coronavirus Infections, Severe acute respiratory syndrome-related coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
